Key result
Elevated plasma levels of ANGPTL8 were associated with 3.8 times higher odds of having hypertension, and both ANGPTL4 and ANGPTL8 levels were significantly increased in hypertensive subjects.
Why the study?
Are plasma and adipose tissue levels of ANGPTL3, ANGPTL4, and ANGPTL8 increased in subjects with hypertension compared to those without?
Cross-Sectional (n=119)
Are plasma and adipose tissue levels of ANGPTL3, ANGPTL4, and ANGPTL8 increased in subjects with hypertension compared to those without?
Odds Ratio: 3.8 (95% CI 1.5–9.8)
p-value: p=0.005
Elevated levels of ANGPTL4 and ANGPTL8 in plasma and adipose tissue are associated with hypertension, suggesting their potential role as biomarkers and therapeutic targets in lipid metabolism regulation.
ANGPTL4/8 levels may mark hypertension; leaves open causal roles or biomarker utility pending prospective validation.
BACKGROUND: Hypertension is a risk factor for both cardiovascular diseases (CVDs) and type 2 diabetes (T2D). Angiopoietin-like proteins (ANGPTLs), mainly ANGPTL3, ANGPTL4 and ANGPTL8, are associated with increased plasma lipid content due to their role in regulating the activity of lipoprotein lipase, a key enzyme in metabolism of the lipoprotein in circulation. Dyslipidaemia is a risk factor for hypertension development; however, the roles of ANGPTL3, ANGPTL4 and ANGPTL8 in subjects with hypertension have not yet been established. This study compared the plasma and adipose tissue levels of ANGPTL3, ANGPTL4 and ANGPTL8 in age- and body mass index-matched subjects with and without hypertension. METHODS: A total of 119 subjects, including 69 hypertensive and 50 non-hypertensive subjects, were enrolled. ANGPTL3, ANGPTL4 and ANGPTL8 plasma levels were measured by ELISA, whereas their levels in adipose tissue were assessed via real-time PCR. RESULTS: We found that ANGPTL4 (202.49 ± 17.44 ng/mL vs. 160.64 ± 10.36 ng/mL, p = 0.04) and ANGPTL8 levels (2310.96 ± 194.88 pg/mL vs. 1583.35 ± 138.27 pg/mL, p = 0.001) were higher in hypertensive subjects than non-hypertensive subjects. However, ANGPTL3 levels were not significantly different between the two populations. Similarly, ANGPTL4 and ANGPTL8 levels were also elevated in subjects with T2D and hypertension than in those with T2D but not hypertension. Additionally, people with highest tertiles of ANGPTL8 had higher odds of having hypertension (odd ratio [OR] = 3.8, 95% confidence interval [CI] = (1.5-9.8), p-Value = 0.005. Similar to its plasma levels, ANGPTL4 and ANGPTL8 were higher in adipose tissue. CONCLUSIONS: In conclusion, our data illustrate that ANGPTL4 and ANGPTL8 levels in both plasma and adipose tissues are increased in subjects with hypertension. The elevated levels of ANGPTL4 and ANGPTL8 in hypertensive subjects highlight their potential involvement, their potential role as biomarkers for hypertension and their therapeutic value in hypertension given their roles in regulating lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Abu‐Farha et al. (2018) conducted a cross-sectional in Hypertension (n=119). Elevated ANGPTL8 levels vs. Lower ANGPTL8 levels was evaluated on Odds of having hypertension (OR 3.8, 95% CI 1.5-9.8, p=0.005). Elevated plasma levels of ANGPTL8 were associated with 3.8 times higher odds of having hypertension, and both ANGPTL4 and ANGPTL8 levels were significantly increased in hypertensive subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: